Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Internal Medicine, 2009
Medical Oncology, 2012
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
neuroendocrine tumors and esophagogastric cancer
Dreyfuss AD, Barsky AR, Plastaras JP, Ben-Josef, Eads JR, Metz JM, Wojcieszynski AP: The efficacy of definitive concurrent proton chemoradiotherapy for esophageal cancer PTCOG-NA abstract book : 2019.
Heckert J, Botterbusch S, Kipnis S, Bennet B, Creamer C, Alderson A, Eads J, Soulen M, Pryma D, Mankoff D, Metz D, Katona B: Initial experience with peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs) at a tertiary care United States center North American Neuroendocrine Tumor Society Abstract book : 2019.
Barsky AR, Dreyfuss AD, Plastaras JP, Ben-Josef E, Eads JR, Metz JM, Wojcieszynski AP: The toxicity profile of definitive concurrent proton chemoradiothearpy for esophageal cancer PTCOG-NA abstract book : 2019.
Heckert JM, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW: Initial experience with peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumor (NET) at a tertiary care United States center Digestive Disease Week abstract book : 2019.
Lee H, Eads JE, Pryma DA: Standardized uptake values on 68Ga-DOTATATE PET/CT predict response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors Radiological Society of North America (RSNA) 2019 Annual Meeting : 2019.
Eads JR, Krishnamurthi SK, Saltzman JN, Bajor DL, Vinayak S, Barnholtz-Sloan J, Meropol NJ, Markowitz SD, Wang Z: Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors J Clin Oncol 36 : 2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB 3rd, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano, T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha, NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G.: NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018 J Natl Compr Canc Netw 16 : 693-702,2018.
Zhao Y, Eads JR, Bajor D, Wang Z: Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials AACR annual meeting abstract book : 2018.
Kim SM, Eads JR: Systemic therapy for the management of neuroendocrine tumor liver metastases Primary and Metastatic Liver Tumors: Treatment Strategy and Evolving Therapies : 2017.
Wu H, Opneja A, Sutter C, Eads JR, Tavri S.: Evidence based review of non-surgical management of colorectal cancer liver metastasis and the evolving role of interventional radiology Digestive Disease Interventions : 2017.
Perelman Center for Advanced Medicine 10th Floor South Pavilion
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.